TY - JOUR
T1 - Fatigue in inflammatory bowel disease and its impact on daily activities
AU - the Swiss IBD Cohort Study Group
AU - Schreiner, Philipp
AU - Rossel, Jean Benoît
AU - Biedermann, Luc
AU - Valko, Philipp O.
AU - Baumann, Christian R.
AU - Greuter, Thomas
AU - Scharl, Michael
AU - Vavricka, Stephan R.
AU - Pittet, Valérie
AU - Juillerat, Pascal
AU - Rogler, Gerhard
AU - von Känel, Roland
AU - Misselwitz, Benjamin
AU - Abdelrahman, Karim
AU - Ademi, Gentiana
AU - Aepli, Patrick
AU - Thomas, Amman
AU - Anderegg, Claudia
AU - Antonino, Anca Teodora
AU - Archanioti, Eva
AU - Arrigoni, Eviano
AU - Aslan, Nurullah
AU - Bakker de Jong, Diana
AU - Balsiger, Bruno
AU - Bastürk, Polat
AU - Bauerfeind, Peter
AU - Becocci, Andrea
AU - Bengoa, José M.
AU - Biedermann, Luc
AU - Binek, Janek
AU - Blattmann, Mirjam
AU - Boehm, Stephan
AU - Boldanova, Tujana
AU - Borovicka, Jan
AU - Braegger, Christian P.
AU - Brand, Stephan
AU - Bravo, Francisco
AU - Brügger, Lukas
AU - Brunner, Simon
AU - Bühr, Patrick
AU - Burk, Sabine
AU - Burri, Emanuel
AU - Butter, Matthias
AU - Buyse, Sophie
AU - Cao, Dahlia Thao
AU - Carstens, Ove
AU - Criblez, Dominique H.
AU - D’Angelo, Fabrizia
AU - Saussure, Philippe
AU - Sauter, Bernhard
N1 - Funding Information:
The authors wish to thank all the patients for their cooperation in answering the questionnaires, all study nurses and medical collaborators of the Swiss IBD cohort study (see Appendix A). Declaration of personal interests: PS: Consulting fees from Pfizer, Takeda and Janssen-Cilag and travel support from Falk, UCB and Pfizer; JBR: No conflict of interest; LB: Consulting fees: Abbvie, MSD, Vifor, Ferring, Pfizer, Janssen, Takeda. Speaker: Takeda, Janssen, Vifor; POV: No conflict of interest; CRB: Grants from Swiss National Science Foundation, Novartis Foundation, HMZ University of Zurich and ETH Zurich, Koetser Foundation. Unrestricted research grants from Roche, AbbVie. Speaker fees from AbbVie, UCB, Roche; TG: Consulting fees with Sanofi-Regeneron and Falk Pharma GmbH, received travel grants from Falk Pharma GmbH and Vifor, and an unrestricted research grant from Novartis; MS: Personal fees: Gilead, Fresenius, Topadur, Takeda, Celltrion, Falk Pharma and Vifor Pharma. Grants: Abbvie, Gilead, Zealand Pharma, Calypso Biotech, NodThera, PharmaBiome, Axalbion, Basilea Pharmaceuticals, Vifor, Takeda, Roche, Herbodee; SRV: Grants: Abbvie, MSD, Vifor, Takeda; Personal Fees: Abbvie, Falk, MSD, Tillots, UCB, Vifor, Takeda, Ferring, Merck, Pfizer, Celgene, Roche, Janssen; VP: No conflict of interest; PJ: No conflict of interest; GR: Grants: Abbvie, Ardeypharm, Falk, MSD, Novartis, Pfizer, Tillots, UCB, Vifor, Takeda, Roche, Zeller, Janssen; Personal Fees: Abbvie, Falk, MSD, Tillots, UCB, Vifor, Takeda, Böhringer Ingelheim, Phadia, Shire, Ferring, Merck, Calypso, Pfizer, Celgene, BMS, Augurix, Roche, Janssen; Non-financial Support: Novartis; Other: Roche, Pharmabiome; RvK: received honoraria from Vifor and Lundbeck Switzerland; BM: advisory board fees from Gilead and Novigenix. He has received speaking fees from Vifor, MSD, and Takeda and traveling fees from Vifor, Novartis, MSD, Gilead and Takeda. BM has received a research grant from MSD unrelated to this work.
Funding Information:
: PS: Consulting fees from Pfizer, Takeda and Janssen‐Cilag and travel support from Falk, UCB and Pfizer; JBR: No conflict of interest; LB: Consulting fees: Abbvie, MSD, Vifor, Ferring, Pfizer, Janssen, Takeda. Speaker: Takeda, Janssen, Vifor; POV: No conflict of interest; CRB: Grants from Swiss National Science Foundation, Novartis Foundation, HMZ University of Zurich and ETH Zurich, Koetser Foundation. Unrestricted research grants from Roche, AbbVie. Speaker fees from AbbVie, UCB, Roche; TG: Consulting fees with Sanofi‐Regeneron and Falk Pharma GmbH, received travel grants from Falk Pharma GmbH and Vifor, and an unrestricted research grant from Novartis; MS: Personal fees: Gilead, Fresenius, Topadur, Takeda, Celltrion, Falk Pharma and Vifor Pharma. Grants: Abbvie, Gilead, Zealand Pharma, Calypso Biotech, NodThera, PharmaBiome, Axalbion, Basilea Pharmaceuticals, Vifor, Takeda, Roche, Herbodee; SRV: Grants: Abbvie, MSD, Vifor, Takeda; Personal Fees: Abbvie, Falk, MSD, Tillots, UCB, Vifor, Takeda, Ferring, Merck, Pfizer, Celgene, Roche, Janssen; VP: No conflict of interest; PJ: No conflict of interest; GR: Grants: Abbvie, Ardeypharm, Falk, MSD, Novartis, Pfizer, Tillots, UCB, Vifor, Takeda, Roche, Zeller, Janssen; Personal Fees: Abbvie, Falk, MSD, Tillots, UCB, Vifor, Takeda, Böhringer Ingelheim, Phadia, Shire, Ferring, Merck, Calypso, Pfizer, Celgene, BMS, Augurix, Roche, Janssen; Non‐financial Support: Novartis; Other: Roche, Pharmabiome; RvK: received honoraria from Vifor and Lundbeck Switzerland; BM: advisory board fees from Gilead and Novigenix. He has received speaking fees from Vifor, MSD, and Takeda and traveling fees from Vifor, Novartis, MSD, Gilead and Takeda. BM has received a research grant from MSD unrelated to this work. Declaration of personal interests
Funding Information:
: The study was funded by the Swiss National Science Foundation (SNF) to the Swiss IBD Cohort 33CS30‐148422. Personal and funding interests
Publisher Copyright:
© 2020 John Wiley & Sons Ltd
PY - 2021/1
Y1 - 2021/1
N2 - Background: Fatigue is a common symptom of chronic inflammation, including inflammatory bowel disease (IBD), resulting in significant impairment in quality of life. Aims: To identify the prevalence of fatigue in a large IBD cohort compared to the general population, address risk factors, and evaluate its impact on daily life. Methods: We evaluated 1208 IBD patients from the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) and 414 healthy controls. Significant fatigue was defined as a visual analogue scale (VAS-F, range 0-10) score ≥ 4. Secondary endpoints were severity of fatigue and its impact on daily activities with the Fatigue Severity Scale (FSS), with a score ≥ 4 indicative of fatigue. Demographic, IBD-related and psychiatric symptoms were assessed with a multivariate analysis of variance (MANOVA) model optimised for prediction of VAS-F (primary outcome) and FSS scores. Results: Overall, 672 IBD patients (55.6%) reported significant fatigue compared to 145 (35%) controls (OR 2.71; 95% CI 2.08-3.54; P < 0.001). In IBD, fatigue also significantly affected daily activities (FSS ≥ 4; 405 (33.5%) IBD patients vs 81 (19.6%) controls, P < 0.001). In the MANOVA model, fatigue levels were associated with female gender (coefficient 0.839; 0.556 - 1.123; P < 0.001), younger age at diagnosis (−0.031 per year; −0.042– −0.019; P < 0.001), shorter disease duration (−0.036 per year; −0.050– −0.022; P < 0.001), nocturnal diarrhoea (0.718; 0.295-1.141; P = 0.001), low educational level (P = 0.034) and symptoms of depression and anxiety. Conclusions: Fatigue is both more frequent and more severe in patients with IBD than in the general population.
AB - Background: Fatigue is a common symptom of chronic inflammation, including inflammatory bowel disease (IBD), resulting in significant impairment in quality of life. Aims: To identify the prevalence of fatigue in a large IBD cohort compared to the general population, address risk factors, and evaluate its impact on daily life. Methods: We evaluated 1208 IBD patients from the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) and 414 healthy controls. Significant fatigue was defined as a visual analogue scale (VAS-F, range 0-10) score ≥ 4. Secondary endpoints were severity of fatigue and its impact on daily activities with the Fatigue Severity Scale (FSS), with a score ≥ 4 indicative of fatigue. Demographic, IBD-related and psychiatric symptoms were assessed with a multivariate analysis of variance (MANOVA) model optimised for prediction of VAS-F (primary outcome) and FSS scores. Results: Overall, 672 IBD patients (55.6%) reported significant fatigue compared to 145 (35%) controls (OR 2.71; 95% CI 2.08-3.54; P < 0.001). In IBD, fatigue also significantly affected daily activities (FSS ≥ 4; 405 (33.5%) IBD patients vs 81 (19.6%) controls, P < 0.001). In the MANOVA model, fatigue levels were associated with female gender (coefficient 0.839; 0.556 - 1.123; P < 0.001), younger age at diagnosis (−0.031 per year; −0.042– −0.019; P < 0.001), shorter disease duration (−0.036 per year; −0.050– −0.022; P < 0.001), nocturnal diarrhoea (0.718; 0.295-1.141; P = 0.001), low educational level (P = 0.034) and symptoms of depression and anxiety. Conclusions: Fatigue is both more frequent and more severe in patients with IBD than in the general population.
UR - http://www.scopus.com/inward/record.url?scp=85096687358&partnerID=8YFLogxK
U2 - 10.1111/apt.16145
DO - 10.1111/apt.16145
M3 - Article
C2 - 33159475
AN - SCOPUS:85096687358
SN - 0269-2813
VL - 53
SP - 138
EP - 149
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 1
ER -